Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
SWOG Cancer Research Network
Thomas Jefferson University
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Stanford University
Northwestern University
University of Washington
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
M.D. Anderson Cancer Center
SWOG Cancer Research Network
National Cancer Institute (NCI)
University of California, San Francisco
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHSU Knight Cancer Institute
Northwestern University
Northwestern University
University of Washington
Academic and Community Cancer Research United
Stanford University
Icahn School of Medicine at Mount Sinai
Mayo Clinic
National Cancer Institute (NCI)